3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Lung Neoplasms
2
Hematologic Neoplasms
2
Gastrointestinal Stromal Tumors
2
Advanced Malignancies
2
Solid Tumor
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Interventions
Dexamethasone
64
Cyclophosphamide
35
pomalidomide
34
Lenalidomide
34
Rituximab
31
Bortezomib
30
venetoclax
28
fludarabine
27
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
17
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Injections
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
tanespimycin
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled